Aclaris Therapeutics
ACRS
ACRS
137 hedge funds and large institutions have $480M invested in Aclaris Therapeutics in 2023 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 61 increasing their positions, 34 reducing their positions, and 16 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
1.76% less ownership
Funds ownership: 100.6% → 98.84% (-1.8%)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
35% less capital invested
Capital invested by funds: $737M → $480M (-$257M)
Holders
137
Holding in Top 10
4
Calls
$22.1M
Puts
$15.8M
Top Buyers
| 1 | +$25.4M | |
| 2 | +$8.55M | |
| 3 | +$7.82M | |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$5.1M |
| 5 |
ACM
Altium Capital Management
New York
|
+$2.76M |
Top Sellers
| 1 | -$30.1M | |
| 2 | -$15.4M | |
| 3 | -$7.36M | |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$6.39M |
| 5 |
TCM
TCG Crossover Management
Palo Alto,
California
|
-$5.49M |